Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)

Home  /  National Uptake and Case Studies  /  Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment. (Core HTA 2)
CountryAgencyStatusLinkDetails on adaptation processContact information
CroatiaAAZ2015Link to the summarySummary of information from the report for decision makers and websiteMirjana Huic (Mirjana.Huic@aaz.hr)
SpainISCIII2016Summary of information from the reportIñaki Imaz
imaz@isciii.es